Full history for every metric is available with a Kvantra account

Stock profile

Codex DNA, Inc. (DNAY)

Country: United States of AmericaSector: HealthcareIndustry: Medical - DevicesExchange: NASDAQ

Delisted · last close 3 Jan 2023

Current price
1.30 USD+8.33%
Last close 3 Jan 2023
Benchmarks

Key financial summary

Financials in USD
201720182019202020212022
Total revenue$m---71127
Operating profit$m-50
Net profit$m----18-39-48
EPS reported$-1.64
Operating cashflow per share$-1.31
Capex per share$0.15
FCF per share$-1.47
Free cash flow$m-43
Net debt$m-22
Book value equity$m47
Book value per share$1.58
Number of sharesm29.46
DPS (TTM paid)$0.00

Financial summary

Financials in USD
201720182019202020212022
Value
P/E TTMx-
P/B LTMx0.76
P/S LTMx1.29
P/FCF LTMx-0.82
EV/EBITDA LTMx-0.57
EV/Sales LTMx0.96
Earnings Yield LTM%-136.96%
FCF Yield%-122.14%
Quality
ROE%-103.99%
ROIC%-72.54%
Operating margin%-181.20%
Gross margin%56.84%
FCF/Sales%-157.40%
Growth and momentum
EPS Growth YoY%-
Sales Growth YoY%+148.44%
Net Income Growth YoY%-
FCF Growth%-
Operating Profit Growth%-
Dividend and capital structure
Dividend Yield%0.00%
Dividend Growth%0.00%
Payout Ratio%0.00%
FCF/Debtx-2.02
Net Debt/EBITDAx0.19
EBIT/Net interestx40.85
Net debt/market cap%-62.65%
Net debt/Equityx-0.48
Gross debt/equityx0.46

Company overview

Operating in the synthetic biology sector, Codex DNA, Inc. develops, manufactures, and sells advanced instruments, reagents, and complementary services. Its primary customer base comprises pharmaceutical firms and academic laboratories worldwide, though it also extends its offerings to government institutions, contract research organizations, and other synthetic biology companies. The company's innovative product portfolio includes the BioXp system, designed to transform digital DNA sequences into usable synthetic DNA, alongside the intuitive BioXp portal, an online platform facilitating DNA sequence design and assembly into chosen vectors. Researchers can also access BioXp kits, which supply essential building blocks and reagents, including the proprietary Gibson Assembly brand, for specific synthetic biology applications. Further support is provided through cloud-based scripts and specialized benchtop reagents for processing products generated by the BioXp system. Moreover, Codex DNA offers Biofoundry Services, allowing clients to commission and receive endpoint-ready BioXp products like genes, clones, cell-free amplified DNA, and variant libraries, in addition to providing short oligo ligation assembly enzymatic DNA synthesis. Established in 2011 and headquartered in San Diego, California, the company rebranded as Codex DNA, Inc. in March 2020, having previously been known as SGI-DNA, Inc.

WebsiteN/A
IndustryMedical - Devices
Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Delisted · last close 3 Jan 2023

Codex DNA, Inc. (DNAY)

DNAY · NASDAQ · Healthcare
1.30 USD+8.33%
Benchmarks
Financialsin USD
20212022
About

Operating in the synthetic biology sector, Codex DNA, Inc. develops, manufactures, and sells advanced instruments, reagents, and complementary services. Its primary customer base comprises pharmaceutical firms and academic laboratories worldwide, though it also extends its offerings to government institutions, contract research organizations, and other synthetic biology companies. The company's innovative product portfolio includes the BioXp system, designed to transform digital DNA sequences into usable synthetic DNA, alongside the intuitive BioXp portal, an online platform facilitating DNA sequence design and assembly into chosen vectors. Researchers can also access BioXp kits, which supply essential building blocks and reagents, including the proprietary Gibson Assembly brand, for specific synthetic biology applications. Further support is provided through cloud-based scripts and specialized benchtop reagents for processing products generated by the BioXp system. Moreover, Codex DNA offers Biofoundry Services, allowing clients to commission and receive endpoint-ready BioXp products like genes, clones, cell-free amplified DNA, and variant libraries, in addition to providing short oligo ligation assembly enzymatic DNA synthesis. Established in 2011 and headquartered in San Diego, California, the company rebranded as Codex DNA, Inc. in March 2020, having previously been known as SGI-DNA, Inc.

IndustryMedical - Devices
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free